Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | TAS2R38 | P59533 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | CDK9 | P50750 | 1/20 | 0.58 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 1/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3070807 | 0.85 | ALDH1A1 (0.70) | ALDH1A1TAS2R38HSD17B10EPHX1SMN1; SMN2 | |
| SCHEMBL3070810 | 0.84 | ALDH1A1 (0.56) | ALDH1A1TAS2R38HSD17B10EPHX1SMN1; SMN2 | |
| SCHEMBL3073451 | 0.82 | ALDH1A1 (0.61) | ALDH1A1TAS2R38HSD17B10EPHX1SMN1; SMN2 | |
| SCHEMBL19357168 | 0.80 | EPHX1 (0.56) | ALDH1A1TAS2R38HSD17B10EPHX1SMN1; SMN2 | |
| SCHEMBL3609840 | 0.80 | ALDH1A1 (0.64) | ALDH1A1TAS2R38HSD17B10EPHX1SMN1; SMN2 | |
| SCHEMBL3073447 | 0.78 | ALDH1A1 (0.70) | ALDH1A1TAS2R38HSD17B10EPHX1SMN1; SMN2 | |
| SCHEMBL3271863 | 0.75 | EPHX2 (0.64) | ALDH1A1TAS2R38HSD17B10EPHX1SMN1; SMN2 | |
| SCHEMBL3426515 | 0.75 | TP53 (0.64) | ALDH1A1TAS2R38HSD17B10EPHX1SMN1; SMN2 | |
| SCHEMBL3271860 | 0.75 | EPHX2 (0.64) | ALDH1A1TAS2R38HSD17B10EPHX1SMN1; SMN2 | |
| SCHEMBL616739 | 0.75 | PTPN11 (0.75) | HSD17B10EPHX1SMN1; SMN2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998401-B2 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | SUNTORY LIMITED (JP) | 2006-02-14 | — | — | US | disclosed |
| EP-1165509-B1 | METHOD OF PRODUCING 3,4-DIHYDROPROLINES AND 3,4-DEHYDROPIPERIDINES | ABBOTT GMBH & CO KG (DE) | 2004-10-06 | — | — | EP | disclosed |
| EP-1045693-B1 | AMINOPHENOXYACETIC ACID DERIVATIVES AS NEUROPROTECTANTS | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-06-30 | — | — | EP | disclosed |
| US-20040063748-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| US-6579971-B1 | Derivatives by reacting with a strong base and compound of given formula; hydrolysis; useful intermediates for the synthesis of dyes, pesticides or drugs (thrombin inhibitors) | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-17 | — | — | US | disclosed |
| US-6559146-B1 | Neuroprotective effects by inducing calbindin D28Kd, one of Ca2+-binding proteins | SUNTORY LIMITED (JP) | 2003-05-06 | — | — | US | disclosed |
| EP-1165509-A1 | METHOD OF PRODUCING 3,4-DIHYDROPROLINES AND 3,4-DEHYDROPIPERIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-02 | — | — | EP | disclosed |
| EP-1045693-A1 | AMINOPHENOXYACETIC ACID DERIVATIVES AS NEUROPROTECTANTS | SUNTORY LIMITED (JP) | 2000-10-25 | — | — | EP | disclosed |
| WO-2000058284-A1 | METHOD OF PRODUCING 3,4-DIHYDROPROLINES AND 3,4-DEHYDROPIPERIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-05 | — | — | WO | disclosed |
| US-6117840-A | INHIBITS BINDING BETWEEN VLA-4 RECEPTOR EXPRESSED ON INFLAMMATORY LEUKOCYTES AND FIBRONECTIN CS-1 PEPTIDE EXPRESSED ON ENDOTHELIAL CELLS THAT ARE INVOLVED IN IMMUNOINFLAMMATORY DISEASE STATES | CYTEL CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| US-5936065-A | PRODRUG AS ANTIINFLAMMATORY AGENT FOR AUTOIMMUNE DISEASES; FOR SUPPRESSING BINDING OF INFLAMMATORY CELLS TO ENDOTHELIAL CELLS THAT EXPRESS THE CS-1 PORTION OF FIBRONECTIN ON THEIR SURFACES | CYTEL CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0737204-A4 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORP (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5844078-A | Phenyl peptides, method for preparing same, and pharmaceutical compositions containing said peptides | LABORATORIE LAPHAL (FR) | 1998-12-01 | — | — | US | disclosed |
| US-5821231-A | TREATMENT OF IMMUNOINFLAMMATORY CONDITIONS | CYTEL CORPORATION (US) | 1998-10-13 | — | — | US | disclosed |
| US-5770573-A | CS-1 peptidomimetics, compositions and methods of using the same | CYTEL CORPORATION (US) | 1998-06-23 | — | — | US | disclosed |
| US-5688913-A | OLIGOPEPTIDES AS ANTIINFLAMMATORY AGENTS | CYTEL CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0787143-A2 | PHENYL PEPTIDES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID PEPTIDES | LABORATOIRE LAPHAL (FR) | 1997-08-06 | — | — | EP | disclosed |
| WO-1997001576-A2 | PHENYL PEPTIDES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID PEPTIDES | LABORATOIRE LAPHAL (FR) | 1997-01-16 | — | — | WO | disclosed |
| EP-0737204-A1 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORPORATION (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995015973-A1 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063748-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | FABP7, SLC1A2, CAMK2A | ALDH1A1 1079/4885TAS2R38 2039/4885HSD17B10 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.